Showing 5091-5100 of 6964 results for "".
- Bristol Myers Squibb Advances Melanoma Drug Candidate Opdivo in US and Europehttps://practicaldermatology.com/news/bristol-myers-squibb-advances-melanoma-drug-candidate-opdivo-in-us-and-europe/2461583/Bristol Myers Squibb announced that the FDA has accepted the supplemental Biologics License Application (BLA) for Opdivo (nivolumab) as monotherapy in the adjuvant setting for the treatment of patients with completely resected stage IIB or IIC melanoma. The company also announced t
- Baby Dove Launches #BabySkin Advice on TikTok with Top Dermatologists and Pediatricianshttps://practicaldermatology.com/news/baby-dove-launches-babyskin-advice-on-tiktok-with-top-dermatologists-and-pediatricians/2461582/Baby Dove is launching #BabySkin Advice,' on TikTok The series provides expert advice from dermatologists and pediatricians to help parents in search of trusted products to care for their newborns unique and delicate skin needs. The #BabySkin Advice series will run from&n
- BeautyHealth Acquires SkinStylushttps://practicaldermatology.com/news/beautyhealth-acquires-skinstylus/2461579/The Beauty Health Company is set to acquire SkinStylus, a US Food and Drug Adminstrayion -cleared microneedling device. The agreement represents a key step forward in BeautyHealth’s portfolio build-up strategy. Upon successful integration of SkinStylus into the BeautyHealth
- Study: Plugging Immune Cell Leakage from Tumors Could Improve MelanomaTreatmenthttps://practicaldermatology.com/news/study-plugging-immune-cell-leakage-from-tumors-could-improve-melanomatreatment/2461578/The number of specialized immune cells available for fighting skin cancer double when a new treatment blocks their escape from melanoma tumors, according to new research out of NYU Langone Health’s Perlmutter Cancer Center Combining a chemical blocker of immune cell exit with
- Garnier Nutrisse Announces Drew Barrymore as Brand Ambassadorhttps://practicaldermatology.com/news/garnier-nutrisse-announces-drew-barrymore-as-brand-ambassador/2461577/Drew Barrymore is the new brand ambassador for Garnier Nutrisse, an expansion to her current role with the Garnier portfolio. Barrymore's role debuts with a creative campaign highlighting Garnier Nutrisse's new and improved Nourishing Color Crème formula for nourished hai
- Incyte Receives Positive CHMP Opinion for Opzelura Cream for the Treatment of Non-Segmental Vitiligohttps://practicaldermatology.com/news/incyte-receives-positive-chmp-opinion-for-opzelura-cream-for-the-treatment-of-non-segmental-vitiligo/2461576/The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of ruxolitinib cream (Opzelura) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
- Biomarkers May Predict AD Developmenthttps://practicaldermatology.com/news/biomarkers-may-predict-ad-development/2461575/An immune and lipid profile on the surface of the skin of infants may predict the development of atopic dermatitis months before the onset of illness. “The holy grail to deal with atopic dermatitis is to prevent it,” says study author
- Cetaphil Launches Initiative to Raise Awareness of Connection Between Clothing and Sensitive Skinhttps://practicaldermatology.com/news/cetaphil-launches-initiative-to-raise-awareness-of-connection-between-clothing-and-sensitive-skin/2461567/Cetaphil announced it is launching a new initiative this month that aims to raise awareness of the connection between our clothes and skin. The initiative includes a partnership with Hillary Taymour, designer and founder of fashion house Collina Strada, and board-certified dermatologist
- ASA Renews Support of SPOTS Programhttps://practicaldermatology.com/news/asa-renews-support-of-spots-program/2461565/The American Skin Association (ASA) announced the renewal of its support for the SPOTS (Sun Protection Outreach Teaching by Students) program. SPOTS is a community outreach program designed to teach students from preschool through high school about the importance of early detectio
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu